Postlicensure safety surveillance for varicella vaccine
- PMID: 10979114
- DOI: 10.1001/jama.284.10.1271
Postlicensure safety surveillance for varicella vaccine
Erratum in
- JAMA 2000 Dec 27;284(24):3129
Abstract
Context: Since its licensure in 1995, the extensive use of varicella vaccine and close surveillance of the associated anecdotal reports of suspected adverse effects provide the opportunity to detect potential risks not observed before licensure because of the relatively small sample size and other limitations of clinical trials.
Objectives: To detect potential hazards, including rare events, associated with varicella vaccine, and to assess case reports for clinical and epidemiological implications.
Design and setting: Postlicensure case-series study of suspected vaccine adverse events reported to the US Vaccine Adverse Event Reporting System (VAERS) from March 17, 1995, through July 25, 1998.
Main outcome measures: Numbers of reported adverse events, proportions, and reporting rates (reports per 100,000 doses distributed).
Results: VAERS received 6574 case reports of adverse events in recipients of varicella vaccine, a rate of 67.5 reports per 100,000 doses sold. Approximately 4% of reports described serious adverse events, including 14 deaths. The most frequently reported adverse events were rashes, possible vaccine failures, and injection site reactions. Misinterpretation of varicella serology after vaccination appeared to account for 17% of reports of possible vaccine failures. Among 251 patients with herpes zoster, 14 had the vaccine strain of varicella zoster virus (VZV), while 12 had the wild-type virus. None of 30 anaphylaxis cases was fatal. An immunodeficient patient with pneumonia had the vaccine strain of VZV in a lung biopsy. Pregnant women occasionally received varicella vaccine through confusion with varicella zoster immunoglobulin. Although the role of varicella vaccine remained unproven in most serious adverse event reports, there were a few positive rechallenge reports and consistency of many cases with syndromes recognized as complications of natural varicella.
Conclusion: Most of the reported adverse events associated with varicella vaccine are minor, and serious risks appear to be rare. We could not confirm a vaccine etiology for most of the reported serious events; several will require further study to clarify whether varicella vaccine plays a role. Education is needed to ensure appropriate use of varicella serologic assays and to eliminate confusion between varicella vaccine and varicella zoster immunoglobulin. JAMA. 2000;284:1271-1279
Similar articles
-
Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.Hum Vaccin Immunother. 2018;14(8):1963-1969. doi: 10.1080/21645515.2018.1456598. Epub 2018 May 18. Hum Vaccin Immunother. 2018. PMID: 29580194 Free PMC article.
-
Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005.J Infect Dis. 2008 Mar 1;197 Suppl 2:S170-7. doi: 10.1086/522161. J Infect Dis. 2008. PMID: 18419393
-
The safety profile of varicella vaccine: a 10-year review.J Infect Dis. 2008 Mar 1;197 Suppl 2:S165-9. doi: 10.1086/522125. J Infect Dis. 2008. PMID: 18419392 Review.
-
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. MMWR Surveill Summ. 2003. PMID: 12825543
-
Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006-2020.J Infect Dis. 2022 Oct 21;226(Suppl 4):S431-S440. doi: 10.1093/infdis/jiac306. J Infect Dis. 2022. PMID: 36265846 Review.
Cited by
-
Vaccines for preventing herpes zoster in older adults.Cochrane Database Syst Rev. 2023 Oct 2;10(10):CD008858. doi: 10.1002/14651858.CD008858.pub5. Cochrane Database Syst Rev. 2023. PMID: 37781954 Review.
-
Safety of Interchanging the Live Attenuated MAV/06 Strain and OKA Strain Varicella Vaccines in Children.Vaccines (Basel). 2023 Aug 31;11(9):1442. doi: 10.3390/vaccines11091442. Vaccines (Basel). 2023. PMID: 37766118 Free PMC article.
-
Rational Design of a Skin- and Neuro-Attenuated Live Varicella Vaccine: A Review and Future Perspectives.Viruses. 2022 Apr 20;14(5):848. doi: 10.3390/v14050848. Viruses. 2022. PMID: 35632591 Free PMC article. Review.
-
Health technology assessment of varicella vaccine in the Armed Forces.Med J Armed Forces India. 2022 Apr;78(2):213-220. doi: 10.1016/j.mjafi.2021.06.010. Epub 2021 Aug 13. Med J Armed Forces India. 2022. PMID: 35463553 Free PMC article.
-
Clinical Manifestations of Herpes Zoster Associated with Complications in Children.Children (Basel). 2021 Sep 24;8(10):845. doi: 10.3390/children8100845. Children (Basel). 2021. PMID: 34682110 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources